Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC).
Saved in:
| Title: | Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC). |
|---|---|
| Authors: | Parimi S; Department of Medical Oncology, BC Cancer Agency, Vancouver Cancer Centre, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada., Eliasziw M; Tufts University, Boston, MA, USA., North S; Cross Cancer Institute, Edmonton, AB, Canada., Trudeau M; Medicine Hat Cancer Centre, Medicine Hat, AB, Canada., Winquist E; London Regional Cancer Centre, London, ON, Canada., Chi KN; Department of Medical Oncology, BC Cancer Agency, Vancouver Cancer Centre, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada., Ruether D; Tom Baker Cancer Centre, Calgary, AB, Canada., Cheng T; Tom Baker Cancer Centre, Calgary, AB, Canada., Eigl BJ; Department of Medical Oncology, BC Cancer Agency, Vancouver Cancer Centre, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada. Bernie.Eigl@bccancer.bc.ca. |
| Source: | Investigational new drugs [Invest New Drugs] 2016 Dec; Vol. 34 (6), pp. 771-776. Date of Electronic Publication: 2016 Aug 26. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Multicenter Study |
| Journal Info: | Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
